Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2016 Health Care Conference. Siggi Olafsson will present on Tuesday, May 10, 2016 at 8:40 AM PT.
|
What: |
Teva Presentation at the Bank of America Merrill Lynch Healthcare Conference | |||
|
Who: |
Siggi Olafsson, President and CEO, Global Generic Medicines, | |||
|
|
Teva Pharmaceutical Industries Ltd. |
|||
|
When: |
Tuesday, May 10, 2016 | |||
|
Where: |
||||
|
How: |
Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website. |
|||
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509005969/en/
Teva Pharmaceutical Industries Ltd.
IR Contacts:
United
States
Kevin C. Mannix, 215-591-8912
or
United
States
Ran Meir, 215-591-3033
or
Israel
Tomer
Amitai, 972 (3) 926-7656
or
PR Contacts:
Israel
Iris
Beck Codner, 972 (3) 926-7246
or
United States
Denise
Bradley, 215-591-8974
Source: Teva Pharmaceutical Industries Ltd.